| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1528-1167.2010.02772.X |
| P8608 | Fatcat ID | release_b6sfvo5pjngbjpwqgxlmnh2w44 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1528-1167.2010.02772.x |
| https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2010.02772.x | ||
| P698 | PubMed publication ID | 21070215 |
| P5875 | ResearchGate publication ID | 47754201 |
| P50 | author | Anthony Marson | Q95965563 |
| Karla Hemming | Q91134793 | ||
| P2093 | author name string | Jane L. Hutton | |
| John M. Wild | |||
| Melissa J. Maguire | |||
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| Visual field constriction in children with epilepsy on vigabatrin treatment | Q28140193 | ||
| The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial | Q28292981 | ||
| Visual field defect associated with vigabatrin: observational cohort study | Q28343662 | ||
| A controlled study of vigabatrin and visual abnormalities | Q28344211 | ||
| Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings | Q28377661 | ||
| Characteristics of a unique visual field defect attributed to vigabatrin | Q28378109 | ||
| Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication | Q31366135 | ||
| Visual field defects in patients taking vigabatrin | Q31472604 | ||
| Visual field changes secondary to vigabatrin treatment | Q32015396 | ||
| Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer | Q33234962 | ||
| Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity | Q33402800 | ||
| Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy. | Q34593907 | ||
| The legacy of vigabatrin in a regional epilepsy clinic | Q34788174 | ||
| Visual field defects associated with vigabatrin therapy | Q35454439 | ||
| Visual field defects in pediatric patients on vigabatrin monotherapy | Q35602594 | ||
| Severe persistent visual field constriction associated with vigabatrin | Q36242274 | ||
| Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control | Q36676442 | ||
| Vigabatrin and visual field defects in pediatric epilepsy patients | Q37313207 | ||
| Clinical pharmacology of vigabatrin | Q38671473 | ||
| Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees | Q39895519 | ||
| Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study | Q43257610 | ||
| Visual function loss from vigabatrin: effect of stopping the drug | Q43505004 | ||
| Vigabatrin-associated visual field defects in children | Q43508140 | ||
| Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor? | Q43509706 | ||
| Vigabatrin visual toxicity: evolution and dose dependence | Q43622918 | ||
| Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making | Q43664148 | ||
| Rapid development of visual field defects associated with vigabatrin therapy | Q43795358 | ||
| No reversion in vigabatrin-associated visual field defects | Q43809209 | ||
| Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study | Q43967953 | ||
| Vigabatrin and retinal changes | Q43985708 | ||
| Visual field and electrophysiological abnormalities due to vigabatrin | Q43985711 | ||
| Visual field constriction in 91 Finnish children treated with vigabatrin | Q44053301 | ||
| Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal | Q44113272 | ||
| Peripheral retinal dysfunction in patients taking vigabatrin | Q44705205 | ||
| Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. | Q44906627 | ||
| Visual defects associated with vigabatrin: a study of epileptic argentine patients | Q46891459 | ||
| Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings | Q48499259 | ||
| Symptomatic and asymptomatic visual loss in patients taking vigabatrin. | Q50516870 | ||
| A pharmacogenetic exploration of vigabatrin-induced visual field constriction | Q57845337 | ||
| Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects | Q73016916 | ||
| Recovery of visual field constriction following discontinuation of vigabatrin | Q73954236 | ||
| The new antiepileptic drugs: a systematic review of their efficacy and tolerability | Q74526025 | ||
| Outer retinal dysfunction in patients treated with vigabatrin | Q77360422 | ||
| Visual field constriction is not limited to children treated with vigabatrin | Q78236906 | ||
| Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin | Q79786356 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 2423-2431 | |
| P577 | publication date | 2010-11-10 | |
| P1433 | published in | Epilepsia | Q5382969 |
| P1476 | title | Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review | |
| Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review | |||
| P478 | volume | 51 |
| Q38752654 | A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience |
| Q55899120 | Adverse effects of antiepileptic drugs |
| Q28069989 | An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs |
| Q36513108 | Antiepileptic drugs 2012: recent advances and trends |
| Q37953583 | Balancing clinical benefits of vigabatrin with its associated risk of vision loss |
| Q30584190 | CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. |
| Q35336784 | Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin? |
| Q50641951 | Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. |
| Q57642468 | Editors’ Introduction |
| Q48009148 | Electroretinographic (ERG) responses in pediatric patients using vigabatrin |
| Q83507718 | Epilepsy: Vigabatrin treatment and visual field loss |
| Q27027982 | Epileptic encephalopathies: new genes and new pathways |
| Q91617355 | Etiology of neonatal seizures and maintenance therapy use: a 10-year retrospective study at Toulouse Children's hospital |
| Q33723915 | Genetic basis of pediatric epilepsy syndromes |
| Q36314739 | Limiting Retinal Toxicity of Vigabatrin in Children With Infantile Spasms |
| Q50624787 | Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients. |
| Q87331771 | Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach |
| Q92649050 | Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives |
| Q52699533 | New GABA modulators protect photoreceptor cells from light-induced degeneration in mouse models. |
| Q37311819 | Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article |
| Q43844526 | Plasma taurine levels are not affected by vigabatrin in pediatric patients |
| Q91739549 | Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of th |
| Q37141468 | Presumed topiramate retinopathy: a case report |
| Q39677260 | Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit |
| Q38185985 | Recent advances in the pharmacotherapy of infantile spasms |
| Q45961350 | Recent and Emerging Anti-seizure Drugs: 2013. |
| Q44969738 | Registry initiated to characterize vision loss associated with vigabatrin therapy |
| Q38946574 | Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent |
| Q38757727 | Stiripentol and vigabatrin current roles in the treatment of epilepsy |
| Q36252559 | Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase |
| Q30455995 | The current evaluation and treatment of infantile spasms among members of the Child Neurology Society |
| Q54486330 | The effectiveness of disc synoptoscope on patients with abnormal binocular vision: a prospective cohort study. |
| Q38106856 | The long-term safety of antiepileptic drugs |
| Q64063874 | The role of optical coherence tomography in therapeutics and conditions, which primarily have systemic manifestations: a narrative review |
| Q30454834 | The safety and tolerability of newer antiepileptic drugs in children and adolescents |
| Q39094490 | Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview |
| Q39130869 | Treatment issues for children with epilepsy transitioning to adult care |
| Q28285293 | Treatment of epileptic encephalopathies |
| Q90625641 | Treatment of infantile spasms |
| Q37937441 | Treatment options for refractory and difficult to treat seizures: focus on vigabatrin |
| Q37953582 | Understanding and interpreting vision safety issues with vigabatrin therapy |
| Q53582038 | Vigabatrin can enhance electroretinographic responses in pigmented and albino rats. |
| Q37987986 | Vigabatrin monotherapy for infantile spasms |
| Q34777907 | Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. |
| Q24187744 | Vigabatrin versus carbamazepine monotherapy for epilepsy |
| Q24203845 | Vigabatrin versus carbamazepine monotherapy for epilepsy |
| Q89696134 | Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice |
| Q38013194 | Vigabatrin-associated retinal damage: potential biochemical mechanisms |
| Q33802718 | Visual Evoked Potentials as a Readout of Cortical Function in Infants With Tuberous Sclerosis Complex |
| Q47993800 | West Syndrome: A Review and Guide for Paediatricians. |
Search more.